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Abstract
Background: Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19)
pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and
dosages, it is important to enable synthesis of existing safety data from clinical trials. However, availability of safety
information is limited by a lack of timely reporting of overall clinical trial results on public registries or through
academic publication. We aimed to analyse the evidence gap in this data by conducting a rapid review of results
posting on ClinicalTrials.gov and in academic publications to quantify the number of trials missing results for drugs
potentially being repurposed for COVID-19.
Methods: ClinicalTrials.gov was searched for 19 drugs that have been identified as potential treatments for COVID-
19. Relevant clinical trials for any prior indication were listed by identifier (NCT number) and checked for results and
for timely result reporting (within 395 days of the primary completion date). Additionally, PubMed and Google
Scholar were searched to identify publications of results not listed on the registry. A second, blinded search of 10%
of trials was conducted to assess reviewer concordance.
Results: Of 3754 completed trials, 1516 (40.4%) did not post results on ClinicalTrials.gov or in the academic literature.
Tabular results were available on ClinicalTrials.gov for 1172 (31.2%) completed trials. A further 1066 (28.4%) had
published results in the academic literature, but did not report results on ClinicalTrials.gov. Key drugs missing clinical
trial results include hydroxychloroquine (37.0% completed trials unreported), favipiravir (77.8%) and lopinavir (40.5%).
Conclusions: There is an important evidence gap for the safety of drugs being repurposed for COVID-19. This
uncertainty could cause unnecessary additional morbidity and mortality during the pandemic. We recommend caution
in experimental drug use for non-severe disease and urge clinical trial sponsors to report missing results retrospectively.
Keywords: Clinical trial transparency, COVID-19 treatment, Coronavirus, Repurposed drugs, Safety information, Adverse
events
Background
Coronavirus disease 2019 (COVID-19) is a pandemic in-
fection caused by severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2). Its global spread has been rapid
and unprecedented, at the time of writing 54.1 million
confirmed cases have been reported with 1.3 million
deaths across 191 countries [1]. Currently, treatment op-
tions for COVID-19 are limited. However, several drugs
developed for other indications have shown promising re-
sults against SARS-CoV-2 in vitro, in animal models, or in
compassionate use trials [2, 3]. Many of these drugs are
now being experimentally repurposed for COVID-19 or
are undergoing clinical trials in humans [4]. Such
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candidates include nitazoxanide, remdesivir, favipiravir,
lopinavir, darunavir, hydroxychloroquine, chloroquine and
ivermectin amongst others [5].
Investigations into the efficacy of these experimental
treatments for COVID-19 are ongoing. Meanwhile, in re-
sponse to positive media coverage, some speculative rather
than evidence-based, governments are stockpiling vast
supplies of these treatments in anticipation of their licenc-
ing for COVID-19. Furthermore, national regulatory insti-
tutions, meant to safeguard against the unsafe use of
drugs, are under increasing pressure to relax approval
standards to accelerate market-entry for COVID-19 treat-
ments. For example, on April 27, 2020, the U.S. Food and
Drug Administration (FDA) approved the antimalarial
drug hydroxychloroquine for emergency treatment of
COVID-19 with unknown optimal dosage and duration of
treatment [6]. However, the efficacy of hydroxychloro-
quine is still under question [7]. Furthermore, it is cardio-
toxic at the higher doses which may be indicated for
COVID-19, causing QT prolongation leading to ventricu-
lar tachycardia and death [8]. Care must be taken not to
lose the rigorous safety standards usually stipulated for
pharmaceuticals, even during a pandemic, to avoid un-
necessary morbidity and mortality worldwide.
As many of these drugs have been used widely in other
indications for years, there should be substantial infor-
mation on safety, tolerability and pharmacokinetics
available in the public domain, including public trial
registries where trial sponsors are expected to upload
summary results. According to the FDA Amendment
Act 2007, the responsible party for applicable clinical tri-
als registered on ClinicalTrials.gov must report results to
a public register within 12 months of the primary com-
pletion date or in some cases risk a fine of $11,569 for
every day results are delayed [9, 10]. Yet, whilst the
International Committee of Medical Journal Editors
(ICMJE) policy requires prospective registration of inter-
ventional studies on a WHO primary registry or on
ClinicalTrials.gov, it does not currently require re-
searchers to report summary results on these registries
before academic publication [11]. Failure to share clin-
ical trial results publicly can have repercussions for
health and public expenditure, especially during a pan-
demic when there should be rapid sharing of results ra-
ther than the conventional academic publishing route.
The effects of poor clinical trial transparency were il-
lustrated by the widespread stockpiling and prescription
of oseltamivir (Tamiflu) during the H1N1 swine flu out-
break in 2009, despite a lack of evidence on safety and
efficacy [12]. When the clinical study reports for this
therapeutic were finally made publicly accessible, the
benefits of the product turned out to be exaggerated and
misrepresented in the journal publications compared to
the underlying data. Following the same H1N1 outbreak,
a novel vaccine (Pandemrix) was rapidly rolled out, but
7 years later, it emerged that the manufacturer had failed
to disclose important internal pharmacovigilance data
showing narcolepsy to be a rare side-effect [13]. Clinical
trial transparency is therefore vital for maximising and
unifying the sharing of data on efficacy as well as safety
in one registry entry and is therefore vital for evidence-
based medicine during this pandemic and beyond.
Public clinical trial registries are an important tool for
transparent collaborative research. On these registries,
safety and efficacy data can be uploaded freely, shortly
after completion of the study, and protocol and data col-
lection methods are still quality assessed [14, 15]. In
contrast, academic publication may take significant pe-
riods of time and can be costly and selective, with time-
intensive writing and review processes. Furthermore,
clinical trial registry data is available free of charge and
can be pooled without concern for silent outcome
switching or publication bias [16–18]. Indeed, inclusion
of unpublished study results from clinical trial registries
in meta-analysis may provide important additional infor-
mation on adverse events and more precise risk esti-
mates than looking at journal publications alone [19].
Moreover, academic publications often fail to disclose all
information on adverse events occurring during clinical
trials; a systematic review comparing journal publica-
tions with related unpublished documents showed a
lower number of adverse events in the published medical
literature for 75% of included studies [20]. Care needs to
be taken during the pandemic as interest in potential
treatments for COVID-19 generates even greater incen-
tive than normal for the publication of studies with posi-
tive results only. Without rapid sharing of datasets for
drugs that may be repurposed for COVID-19, starting
with the timely reporting of primary trial results, sec-
ondary analyses of safety data will be arduous and often
incomplete [14, 21]. This may slow down the biomedical
innovation process and could lead to preventable side ef-
fects occurring in vulnerable patients if safety informa-
tion remains missing. As the pharmaceutical pipeline is
accelerated to address the COVID-19 pandemic, enhan-
cing clinical trial transparency is now more important
than ever.
In this rapid review of ClinicalTrials.gov, we aimed to de-
termine the scale of unpublished clinical trial results. This is
important as a lack of primary data may hinder safety re-
views of repurposed drugs for COVID-19. We reviewed the
number of completed or terminated trials that have not re-
ported due primary trial results for an extensive list of medi-
cations being repurposed for COVID-19. Specifically, we
searched for any trial results from all previous indications for
these drugs that have not been made available to the public,
with no results published on either on the ClinicalTrial.gov
registry or in the academic literature.
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Methods
We selected 19 potential treatments for coronavirus dis-
eases based on information found in potential COVID-
19 treatment reviews [5, 22, 23]. The drugs assessed
were pirfenidone, hydroxychloroquine, azithromycin,
favipiravir, oseltamivir, sarilumab, tocilizumab, remdesi-
vir, leflunomide, interferon-alpha, lopinavir-ritonavir,
darunavir-ritonavir, baloxavir marboxil, umifenovir,
interferon-beta, sofosbuvir, nitazoxanide, APN01 and
ivermectin (Table 1). Synonyms and chemical names for
these drugs were taken from pubchem.ncbi.nlm.nih.gov
(Appendix) [24].
The U.S. clinical trials registry (ClinicalTrials.gov) was
searched for all trials that listed these drugs as an inter-
vention. Results of the search were downloaded on 4
April 2020 [25]. Numbers of trials with and without re-
sults on the registry were recorded. For trials without re-
sults, trial status was determined (completed, ongoing,
suspended, terminated or withdrawn). Trials listing ‘pri-
mary completion date’ in the future were counted as on-
going, if no primary completion date was available then
the study completion date was used. Listed trial status
was used to identify terminated, suspended and with-
drawn trials.
For all trials without results on ClinicalTrials.gov, a
three-step process was followed between 4 and 27 April
2020 to determine whether results were reported else-
where through academic publication (Fig. 1).
1) Publications automatically indexed by clinical trial
identifier (NCT number) on ClinicalTrials.gov were
screened and included based on criteria below. If
multiple publications were listed, the earliest dated
publication was selected.
2) If results were not available on the registry, the
NCT number was used to search and screen
academic publications in PubMed.
3) If the PubMed search did not retrieve an academic
publication, an additional search was conducted in
Google Scholar using the following search terms in
succession: clinical trial identifier; listed title;
intervention name with primary investigator’s
name. For each search, the first twenty results were
screened.
If a publication did not include the clinical trial
identifier, it was cross-referenced with the primary in-
vestigator, study design, intervention, and outcomes
listed on ClinicalTrials.gov to assess relevance. We
excluded publications that had fewer than 500 words,
as well as conference abstracts, posters, presentations
and non-English texts.
Table 1 Trials registered to NCT for repurposed drugs, of which ongoing and suspended or withdrawn. Percentages are of all
registered trials
Generic name Total registered Ongoing Suspended/withdrawn Completed
Pirfenidone 86 30 (34.9%) 2 (2.3%) 54 (62.8%)
Hydroxychloroquine sulfate 233 74 (31.8%) 5 (2.1%) 154 (66.1%)
Azithromycin 457 98 (21.4%) 16 (3.5%) 343 (75.1%)
Favipiravir 12 3 (25.0%) 0 (0.0%) 9 (75.0%)
Oseltamivir 127 18 (14.2%) 8 (6.3%) 101 (79.5%)
Sarilumab 37 19 (51.4%) 0 (0.0%) 18 (48.6%)
Tocilizumab (atlizumab) 360 84 (23.3%) 9 (2.5%) 267 (74.2%)
Remdesivir 12 11 (91.7%) 0 (0.0%) 1 (8.3)
Leflunomide 25 4 (16.0%) 1 (4.0%) 20 (80.0%)
Interferon-alpha 1161 71 (6.1%) 41 (3.5%) 1049 (90.4%)
Lopinavir/ritonavir 1015 66 (6.5%) 22 (2.2%) 927 (91.3%)
Darunavir/ritonavir 246 26 (10.6%) 4 (1.6%) 216 (87.8%)
Baloxavir marboxil 9 4 (44.4%) 0 (0.0%) 5 (55.6%)
Umifenovir 10 8 (80.0%) 0 (0.0%) 2 (20.0%)
Interferon-beta 343 43 (12.5%) 15 (4.4%) 285 (83.1%)
Sofosbuvir 261 75 (28.7%) 10 (3.8%) 176 (67.4%)
Nitazoxanide 57 8 (14.0%) 1 (1.8%) 48 (84.2%)
APN01 (ACE2 analogue) 1 0 (0.0%) 0 (0.0%) 1 (100.0%)
Ivermectin 101 19 (18.8%) 4 (4.0%) 78 (77.2%)
Totals 4553 661 (14.5%) 138 (3.0%) 3754 (82.5%)
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Publications of results were recorded by PMID, DOI
and publication date. Trials with summary results on
ClinicalTrials.gov combined with those with a journal
publication gave a total number of trials with results
where results were found in the public domain. This
allowed approximation of registered trials without results.
Additionally, overdue trials were calculated as any
completed trial with no result on the registry and a pri-
mary completion date before 18 April 2019, 395 days
prior to final analysis (1 year + 30-day grace period). This
is the standard outlined in the FDAAA 2007 and used as
a reference throughout this study despite not all in-
cluded trials being covered by the law [9]. This is also
consistent with international ethical standards for timely
results dissemination of 12 months set by the World
Health Organisation [26].
A second blinded review was conducted by a different
researcher on 10% of trials for each drug to check con-
cordance between reviewers. The protocol during the
second review remained unchanged and researchers
were blinded to the results of the first review. A random
number generator was used to select trials for second re-
view. Concordance was assessed using simple percentage
agreement as well as Cohen’s kappa to further analyse
interrater reliability [27]. Results published between the
dates of first and second review (29 April–9 May 2020)
were not counted in this assessment.
Results
Nineteen drugs were screened, encompassing a total of
4553 clinical trials registered on ClinicalTrials.gov
(Table 1). We excluded 799 of these trials, 661 of which
Fig. 1 Flow chart depicting the methodology used to search for and identify relevant publications for each of the trials listed on CT.gov
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were ongoing (primary completion date in the future)
and 138 of which were suspended or withdrawn. Figure 2
shows the number of trials found on ClinicalTrials.gov,
those excluded from this analysis, and the final results
status of all included trials. All recorded percentages in
text are in relation to the 3754 completed trials, seen in
Table 2.
In sum, our protocol revealed 2238 (59.6%) completed
trials had published results either on the registry or in the
academic literature (Table 2). Of these, 1172 (31.2%) com-
pleted trials had tabular results on ClinicalTrials.gov
(Table 2). A further 1066 (28.4%) completed trials had re-
sults from the literature search, but did not report results
on ClinicalTrials.gov (Table 2). Across the 19 drugs which
may be repurposed for the treatment of COVID-19, 1516
(40.4%) of completed clinical trials listed on ClinicalTrials.
gov were missing results. Figure 3 shows the proportions
of trial results available on ClinicalTrials.gov, available in
the literature, and those with no results available.
Of the 3754 completed studies, 2379 (63.4%) did not
report results on ClinicalTrials.gov within of the 395-day
timeframe mandated by the FDAAA 2007 and the
WHO. Of these trials that did not report results on the
NCT, 1008 (26.9%) had published results in the aca-
demic literature but failed to adhere to reporting best
practices [9]. In the blinded second review of 341 (10%)
trials, percentage agreement was 83.6%, whilst the kappa
was 0.64 indicating ‘substantial agreement’ [27].
Discussion
Of the completed clinical trials for existing drugs that may
be repurposed for COVID-19, 40.4% did not report primary
results, including safety data, on either ClinicalTrials.gov or
through academic publication (Table 2). This shows a large
gap in the evidence base regarding efficacy and adverse ef-
fects of these drugs, which may limit attempts to compre-
hensively review their safety before potential global
distribution for the COVID-19 pandemic. As this review as-
sesses reporting of primary results, which do not necessarily
encompass safety data, the proportion of trials without safety
information may be higher than the reported 40.4%. The
2238 (59.6%) completed studies with available results were
comprised of 1172 (31.2%) with results on the registry and
1066 (28.4%) without results on the registry that had results
from a standardised search of the literature (Table 2). Fur-
thermore, 2379 (63.4%) studies without registry results had a
primary completion date 395 days in the past and were
therefore outside of the timeframe for results publication as
mandated by the FDAAA 2007 and WHO best practice [9].
Although 1008 (26.9%) of these had already published results
in academic literature, they still failed to upload their sum-
mary results on ClinicalTrials.gov. Not all trials included in
this study are covered by the FDAAA 2007, but the 12-
month deadline remains an important benchmark for good
scientific practice [26]. With 40.4% of clinical trial results un-
available for potential COVID-19 treatments, the data for
clinical decision making regarding the safety of these thera-
peutics is limited. If any potential treatments with an incom-
plete evidence base are used during the pandemic, even in
compassionate use programmes, there is a risk of avoidable
harm being done because of missing adverse safety data. An
evidence gap was revealed for drugs which have had exten-
sive media coverage in the context of COVID-19, including
hydroxychloroquine (37.0% without results), favipiravir
(77.8%) and lopinavir (40.5%) [28–30]. These drugs are cur-
rently used in COVID-19 patients and clinical trials across
Fig. 2 Flow diagram displaying the numbers of registered trials identified on CT.gov and the proportion of these which ultimately have no
results available. The number of trials which had results available from various sources or had been withdrawn/suspended or trails for which
results were not yet due are also shown
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the globe, sometimes in novel regimens and doses that are
much higher than those administered in the original trials [7,
31, 32]. Clinicians currently have few treatment options avail-
able, but with greater transparency and proactivity from trial
sponsors regarding the posting of results, there would
be less risk of unforeseen adverse outcomes, especially
in the treatment of mild-moderate COVID-19 as in
the PIONEER trial [31].
We recognise that there are sources of safety data be-
yond clinical trial registries, such as pharmacovigilance
databases. However, these are not always publicly avail-
able. Additionally, there is often no obligation for all ad-
verse events to be reported to pharmacovigilance
registries, in contrast with clinical trial registries. Public
health decision-makers, guideline developers, clinicians,
and patients therefore rely on clinical trial registries, sys-
tematic reviews and meta-analyses to inform treatment
decisions. Evidence gaps and publication bias therefore
have the potential to influence clinical practice and drug
usage worldwide, particularly in a treatment landscape
as changeable as during the COVID-19 pandemic. Clin-
ical decisions based on incomplete evidence can lead to
avoidable morbidity and mortality, especially if unsafe
drugs or ineffective treatments are given on a large scale.
Sponsors and researchers alike carry an ethical
responsibility to make results publicly available. They
owe this to clinical trial participants, who consent to
participate in research in order to contribute to scientific
understanding and improved clinical practice [33].
Our study reveals an important evidence gap re-
garding existing pharmaceuticals potentially being
repurposed for COVID-19. However, the proportion
of studies with results available in the academic litera-
ture given here is an approximation and it is neces-
sary to highlight several limitations to our study.
Firstly, our trial population was limited only to those
registered on ClinicalTrials.gov. Whilst ClinicalTrials.
gov is the largest registry in the world, with over 340,
000 registrations as of writing, and thereby an order
of magnitude greater than the next largest registry,
additional trials on these therapies may have been
registered elsewhere and may not be captured in this
study. However, it is unlikely that trials in other
registries would report at a significantly different rate
to ClinicalTrials.gov. As a second limitation, our
strategy for locating publications included only those
listed on ClinicalTrials.gov and identified through
searches on PubMed and Google Scholar, open-access
resources that should cover a majority of published
clinical research. Including proprietary databases like
Table 2 Number of completed trials registered on ClinicalTrials.gov, of which results have been published on ClinicalTrials.gov or in
the academic literature. Percentages are displayed as a proportion of all completed trials
Generic name Completed Results on NCT Academic publication only Results unreported
Pirfenidone 54 18 (33.3%) 20 (37.0%) 16 (29.6%)
Hydroxychloroquine 154 38 (24.7%) 59 (38.3%) 57 (37.0%)
Azithromycin 343 78 (22.7%) 119 (34.7%) 146 (42.6%)
Favipiravir 9 1 (11.1%) 1 (11.1%) 7 (77.8%)
Oseltamivir 101 38 (37.6%) 18 (17.8%) 45 (44.6%)
Sarilumab 18 13 (72.2%) 2 (11.1%) 3 (16.7%)
Tocilizumab (atlizumab) 267 125 (46.8%) 44 (16.5%) 98 (36.7%)
Remdesivir 1 0 (0.0%) 0 (0.0%) 1 (100%)
Leflunomide 20 5 (25.0%) 4 (20.0%) 11 (55.0%)
Interferon-alpha 1049 347 (33.1%) 301 (28.7%) 401 (38.2%)
Lopinavir/ritonavir 927 287 (31.0%) 265 (28.6%) 375 (40.5%)
Darunavir/ritonavir 216 73 (33.8%) 66 (30.6%) 77 (35.6%)
Baloxavir marboxil 5 2 (40.0%) 0 (0.0%) 3 (60.0%)
Umifenovir 2 0 (0.0%) 2 (100.0%) 0 (0.0%)
Interferon-beta 285 84 (29.5%) 84 (29.5%) 117 (41.1)
Sofosbuvir 176 36 (20.5%) 42 (23.9%) 98 (55.7%)
Nitazoxanide 48 11 (22.9%) 12 (25.0%) 25 (52.1%)
APN01 (ACE2 analogue) 1 0 (0.0%) 1 (100.0%) 0 (0.0%)
Ivermectin 78 16 (20.5%) 26 (33.3%) 36 (46.2%)
Totals 3754 1172 (31.2%) 1066 (28.4%) 1516 (40.4%)
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Scopus or Ovid may have located some additional
publications, yet we do not believe this would have
substantially impacted our overall findings [34]. We
are also aware that trials that were not registered in
the first place, reported results in non-English lan-
guage journals, or published without inclusion of the
NCT number could potentially not have been cap-
tured by our methodology. Finally, searcher hetero-
geneity and difficulty identifying results publication in
the academic literature limits accuracy of any manual
publication search. However, our search strategy was
standardised and produced a high level of agreement
between assessors (83.6%) in a check of a 10% ran-
dom sample. Furthermore, any discordance between
reviewers only reveals the inherent difficulties in find-
ing results for the drugs in question, especially if the
trial identification number was omitted, in conflict
with CONSORT standards [35].
Our findings add to the existing evidence of the
dearth of accurate and timely clinical trial reporting
on public registries. This analysis investigated clinical
trials of existing drugs currently being considered for
use for COVID-19. However, given the diversity of
drug classes included in this report, findings are likely
Fig. 3 Bar chart displaying the proportion of trial results available across all potential COVID-19 therapies—categorised into those registered fully
on CT.gov, those with results available in the academic literature only and those with no results available
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to be representative of many pharmaceuticals. This
presents a major problem for researchers attempting
to summarise safety and efficacy of such drugs by
pooling existing trial data [36]. Since academic publi-
cations often summarise key findings only, secondary
research efforts are impinged by the incomplete pub-
lishing of all trial outcomes. ClinicalTrials.gov, in con-
trast to academic publishing, provides a forum to
share complete safety and efficacy data reports and
facilitates consistent data reporting in a timely man-
ner [14, 15]. Prior research has shown that results
reported to ClincialTrials.gov were often more
complete, especially for safety data, when compared
to matched journal publications [16–18]. However,
the availability of data depends on researchers regis-
tering trials and uploading results in a timely manner,
within 12 months of the primary completion date.
The International Committee of Medical Journal Edi-
tors (ICMJE) and the editorial offices of medical journals
could play an important role in improving the lack of
timely results posting by demanding submission of a link
to summary results on public registries before academic
publication. Yet, this may mean that the publication bias
of positive, ‘publishable’ results could trickle down to
reporting on public registries as no such checks would
exist for the reporting of negative results, which are less
likely to be published in the first place. Furthermore,
public funders and institutional publication funds could
demand that trial sponsors post their results before allo-
cating funding for academic (open-access) publication.
These funding bodies could also deny individual spon-
sors funding if they have violated clinical trial reporting
rules in the past [37], an option currently being consid-
ered by some UK funding bodies. At the very least, jour-
nals should conform to the CONSORT statement in
ensuring that registry identification numbers are clearly
indicated in the abstract, full-text and meta-data of pub-
lished clinical trials in order promote discoverability and
record linkage between registries and publications [35].
Finally, clinical trial sponsors, such as universities, hospi-
tals, public research institutions and pharmaceutical
companies, should themselves work towards improving
their institutional clinical trial reporting performance by
making use of available resources that provide detailed
Appendix
Table 3 Intervention clinicaltrials.gov search terms by generic name of drug
Generic name Search terms
Pirfenidone Pirfenidone OR Esbriet OR Pirespa OR Etuary
Hydroxychloroquine
sulfate
Hydroxycholoroquine OR Plaquenil OR Hydroquin OR Axemal OR Dolquine or Quensyl or Quinoric
Azithromycin Azithromycin OR zithromax OR AzaSite OR Zmax.
Favipiravir Favipiravir OR Avigan OR T-705
Oseltamivir Oseltamivir OR oseltamivir phosphate OR tamiflu OR GS-4104
Sarilumab Surilumab OR Kevzara
Tocilizumab
(atlizumab)
Actemra OR Tocilizumab OR Atlizumab
Remdesivir Remdesivir OR GS-5734
Leflunomide Leflunomide OR arava OR SU101
Interferon-alpha IFN-A OR interferon alpha
Lopinavir/ritonavir Kaletra OR lopinavir OR ritonavir or navir
Darunavir/ritonavir Prezista OR Darunavir OR TMC 114.
Baloxavir marboxil Baloxavir marboxil OR UNII-505CXM6OHG OR 505CXM6OHG OR 1985606-14-1 OR xofluza
Umifenovir Umifenovir OR arbidol OR AR-1I9514 OR UNII-93M09WW4RU OR 131707-25-0
Interferon-beta Interferon-Beta OR ampligen OR Betaseron OR betaferon OR BAY86-5046 OR Interferon beta-1b OR IFN-Beta
Sofosbuvir SOFOSBUVIR OR PSI-7977 OR 1190307-88-0 OR SOVALDI OR GS-7977




Ivermectin IVERMECTIN OR Ivermectin B1a OR Dihydroavermectin B1a OR 22,23-Dihydroavermectin B1a OR ivermectin H2B1a OR UNII-
91Y2202OUW OR CHEBI:63941
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step-by-step instructions of this process [10]. Especially
during the COVID-19 pandemic, it is of great import-
ance that trials sponsors release summary results on
these registries retrospectively to inform decision mak-
ing around the safe usage of existing treatments being
re-purposed for COVID-19.
Conclusions
Overall, our findings reveal a significant evidence gap
for drugs being repurposed for COVID-19. As a result
important information on the safety of these treat-
ments, that should have been reported with primary
results, remains unknown. We suggest that this un-
certainty could cause a large burden of extra morbid-
ity in the global pandemic. We therefore recommend
caution in experimental drug use for non-severe dis-
ease and urge trial sponsors to report missing results
retrospectively. Medicine during the COVID-19 pan-
demic cannot be evidence-based if a large proportion
of the evidence is missing
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